← Encompass Health overview

Encompass Health vs Fresenius Medical Care AG & Co. KGaA: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Encompass Health Corp (EHC)

Q3 2026
▲3

EHC beats and raises again, adds capacity as Medicare rates rise

  • Q2 beat and second guidance raise Encompass Health beat second-quarter expectations, with revenue up 9.6% to $1.6 billion and adjusted EPS of $1.55 ahead of estimates, then raised full-year revenue and profit guidance for the second time this year. Higher expected earnings support a higher stock price.

    The earnings beat and raised outlook are the core new fundamental driver of the stock.

  • Medicare rehab rate increase finalized Federal regulators finalized a rule lifting Medicare payments for inpatient rehabilitation by about 2.3% starting in October. Medicare is a major payer for EHC, so higher set rates lift revenue per patient and helped management raise its outlook.

    A regulatory rate change directly raises EHC's reimbursement and future revenue.

  • Capacity expansion, including first small-format hospital EHC announced its first small-format inpatient rehabilitation hospital in Conroe, Texas, plus a 60-bed replacement hospital in The Woodlands. Adding beds and a new lower-cost model extends its reach into growing communities and supports future growth.

    New hospital projects show how EHC plans to grow revenue beyond current guidance.

  • Insider share sales and debt risk temper the good news The CFO, CEO and general counsel sold shares after the stock hit near a 52-week high, which can unsettle investors. EHC also carries net debt of 41.4% of capital, above the industry average, and shares slipped 1.8% after earnings.

    This is the real counterweight: insider selling and leverage could hold the stock back.

August 2026
▲3

EHC beats and raises again, adds capacity as Medicare rates rise

  • Q2 beat and second guidance raise Encompass Health beat second-quarter expectations, with revenue up 9.6% to $1.6 billion and adjusted EPS of $1.55 ahead of estimates, then raised full-year revenue and profit guidance for the second time this year. Higher expected earnings support a higher stock price.

    The earnings beat and raised outlook are the core new fundamental driver of the stock.

  • Medicare rehab rate increase finalized Federal regulators finalized a rule lifting Medicare payments for inpatient rehabilitation by about 2.3% starting in October. Medicare is a major payer for EHC, so higher set rates lift revenue per patient and helped management raise its outlook.

    A regulatory rate change directly raises EHC's reimbursement and future revenue.

  • Capacity expansion, including first small-format hospital EHC announced its first small-format inpatient rehabilitation hospital in Conroe, Texas, plus a 60-bed replacement hospital in The Woodlands. Adding beds and a new lower-cost model extends its reach into growing communities and supports future growth.

    New hospital projects show how EHC plans to grow revenue beyond current guidance.

  • Insider share sales and debt risk temper the good news The CFO, CEO and general counsel sold shares after the stock hit near a 52-week high, which can unsettle investors. EHC also carries net debt of 41.4% of capital, above the industry average, and shares slipped 1.8% after earnings.

    This is the real counterweight: insider selling and leverage could hold the stock back.

Latest
▲3

EHC beats and raises again, adds capacity as Medicare rates rise

  • Q2 beat and second guidance raise Encompass Health beat second-quarter expectations, with revenue up 9.6% to $1.6 billion and adjusted EPS of $1.55 ahead of estimates, then raised full-year revenue and profit guidance for the second time this year. Higher expected earnings support a higher stock price.

    The earnings beat and raised outlook are the core new fundamental driver of the stock.

  • Medicare rehab rate increase finalized Federal regulators finalized a rule lifting Medicare payments for inpatient rehabilitation by about 2.3% starting in October. Medicare is a major payer for EHC, so higher set rates lift revenue per patient and helped management raise its outlook.

    A regulatory rate change directly raises EHC's reimbursement and future revenue.

  • Capacity expansion, including first small-format hospital EHC announced its first small-format inpatient rehabilitation hospital in Conroe, Texas, plus a 60-bed replacement hospital in The Woodlands. Adding beds and a new lower-cost model extends its reach into growing communities and supports future growth.

    New hospital projects show how EHC plans to grow revenue beyond current guidance.

  • Insider share sales and debt risk temper the good news The CFO, CEO and general counsel sold shares after the stock hit near a 52-week high, which can unsettle investors. EHC also carries net debt of 41.4% of capital, above the industry average, and shares slipped 1.8% after earnings.

    This is the real counterweight: insider selling and leverage could hold the stock back.

Fresenius Medical Care AG & Co. KGaA (FME.XETRA)

Q3 2026
▲2

Fresenius Medical Care: Strong Q2, New Products, China Exit, CEO Change

  • Q2 profit jumps 23%, margin expands, second €1bn buyback launched Fresenius Medical Care's Q2 operating income rose 23% at constant currency, margin expanded, and EPS jumped 28%. A second €1 billion share buyback was launched after completing the first. This signals strong cash generation and management confidence, supporting the share price.

    This is the core financial result that directly drives investor confidence and the stock's valuation.

  • New TherapyWise analytics and HDF study boost product portfolio Fresenius launched TherapyWise, a cloud analytics tool for its NxStage system, and published a study showing its hemodiafiltration (HDF) treatment cuts mortality risk by 28%. These innovations strengthen its product lineup and could drive future sales, especially as HDF expands in the U.S.

    New products and clinical evidence can open new markets and increase demand for the company's treatments.

  • China strategy shift: exits peritoneal dialysis, takes €110m one-time charge Fresenius is refining its China business, exiting peritoneal dialysis and discontinuing the 4008A system, while focusing on advanced in-center therapies. This will cost about €110 million in one-time charges but is not expected to hurt future revenue. The move aims to improve long-term competitiveness.

    The China restructuring is a significant strategic change with a near-term cost but potential long-term benefit.

  • CEO succession: Shervin Korangy to replace Helen Giza Fresenius named Shervin Korangy as new CEO, succeeding Helen Giza who led a €1.2 billion cost-cutting program. Leadership changes can bring fresh strategy but also uncertainty. The market will watch for continuity or shifts in direction.

    A CEO change is a major event that can affect investor sentiment and future strategy.

August 2026
▲2

Fresenius Medical Care: Strong Q2, New Products, China Exit, CEO Change

  • Q2 profit jumps 23%, margin expands, second €1bn buyback launched Fresenius Medical Care's Q2 operating income rose 23% at constant currency, margin expanded, and EPS jumped 28%. A second €1 billion share buyback was launched after completing the first. This signals strong cash generation and management confidence, supporting the share price.

    This is the core financial result that directly drives investor confidence and the stock's valuation.

  • New TherapyWise analytics and HDF study boost product portfolio Fresenius launched TherapyWise, a cloud analytics tool for its NxStage system, and published a study showing its hemodiafiltration (HDF) treatment cuts mortality risk by 28%. These innovations strengthen its product lineup and could drive future sales, especially as HDF expands in the U.S.

    New products and clinical evidence can open new markets and increase demand for the company's treatments.

  • China strategy shift: exits peritoneal dialysis, takes €110m one-time charge Fresenius is refining its China business, exiting peritoneal dialysis and discontinuing the 4008A system, while focusing on advanced in-center therapies. This will cost about €110 million in one-time charges but is not expected to hurt future revenue. The move aims to improve long-term competitiveness.

    The China restructuring is a significant strategic change with a near-term cost but potential long-term benefit.

  • CEO succession: Shervin Korangy to replace Helen Giza Fresenius named Shervin Korangy as new CEO, succeeding Helen Giza who led a €1.2 billion cost-cutting program. Leadership changes can bring fresh strategy but also uncertainty. The market will watch for continuity or shifts in direction.

    A CEO change is a major event that can affect investor sentiment and future strategy.

Latest
▲2

Fresenius Medical Care: Strong Q2, New Products, China Exit, CEO Change

  • Q2 profit jumps 23%, margin expands, second €1bn buyback launched Fresenius Medical Care's Q2 operating income rose 23% at constant currency, margin expanded, and EPS jumped 28%. A second €1 billion share buyback was launched after completing the first. This signals strong cash generation and management confidence, supporting the share price.

    This is the core financial result that directly drives investor confidence and the stock's valuation.

  • New TherapyWise analytics and HDF study boost product portfolio Fresenius launched TherapyWise, a cloud analytics tool for its NxStage system, and published a study showing its hemodiafiltration (HDF) treatment cuts mortality risk by 28%. These innovations strengthen its product lineup and could drive future sales, especially as HDF expands in the U.S.

    New products and clinical evidence can open new markets and increase demand for the company's treatments.

  • China strategy shift: exits peritoneal dialysis, takes €110m one-time charge Fresenius is refining its China business, exiting peritoneal dialysis and discontinuing the 4008A system, while focusing on advanced in-center therapies. This will cost about €110 million in one-time charges but is not expected to hurt future revenue. The move aims to improve long-term competitiveness.

    The China restructuring is a significant strategic change with a near-term cost but potential long-term benefit.

  • CEO succession: Shervin Korangy to replace Helen Giza Fresenius named Shervin Korangy as new CEO, succeeding Helen Giza who led a €1.2 billion cost-cutting program. Leadership changes can bring fresh strategy but also uncertainty. The market will watch for continuity or shifts in direction.

    A CEO change is a major event that can affect investor sentiment and future strategy.